ANZEMET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Anzemet, and what generic alternatives are available?
Anzemet is a drug marketed by Validus Pharms and is included in two NDAs.
The generic ingredient in ANZEMET is dolasetron mesylate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolasetron mesylate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANZEMET?
- What are the global sales for ANZEMET?
- What is Average Wholesale Price for ANZEMET?
Summary for ANZEMET
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,834 |
| Drug Prices: | Drug price information for ANZEMET |
| What excipients (inactive ingredients) are in ANZEMET? | ANZEMET excipients list |
| DailyMed Link: | ANZEMET at DailyMed |
Recent Clinical Trials for ANZEMET
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Pittsburgh | Phase 2 |
| David A. Clump, MD, PhD | Phase 2 |
| University of Southern California | N/A |
Pharmacology for ANZEMET
| Drug Class | Serotonin-3 Receptor Antagonist |
| Mechanism of Action | Serotonin 3 Receptor Antagonists |
US Patents and Regulatory Information for ANZEMET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-002 | Sep 11, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | ANZEMET | dolasetron mesylate | TABLET;ORAL | 020623-001 | Sep 11, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-001 | Sep 11, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-003 | Dec 11, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Validus Pharms | ANZEMET | dolasetron mesylate | TABLET;ORAL | 020623-002 | Sep 11, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ANZEMET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-002 | Sep 11, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-003 | Dec 11, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | ANZEMET | dolasetron mesylate | TABLET;ORAL | 020623-001 | Sep 11, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | ANZEMET | dolasetron mesylate | TABLET;ORAL | 020623-002 | Sep 11, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | ANZEMET | dolasetron mesylate | TABLET;ORAL | 020623-002 | Sep 11, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | ANZEMET | dolasetron mesylate | INJECTABLE;INJECTION | 020624-001 | Sep 11, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ANZEMET
See the table below for patents covering ANZEMET around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1329203 | ESTERS DE L'HEXAHYDRO-8HYDROXY-2, 6-METHANO-2H-QUINOLIZIN-3 (4H)-ONE ET COMPOSES CONNEXES (ESTERS OF HEXAHYDRO-8-HYDROXY-2, 6-METHANO-2H- QUINOLIZIN-3(4H)-ONE AND RELATED COMPOUNDS) | ⤷ Sign Up |
| Greece | 3018299 | ⤷ Sign Up | |
| Japan | 2542225 | ⤷ Sign Up | |
| Canada | 1325634 | ESTERS D'HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H-QUINOLIZIN-3 (4H)-ONE, ET COMPOSES ANNEXES (ESTERS OF HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H- QUINOLIZIN-3(4H)-ONE AND RELATED COMPOUNDS) | ⤷ Sign Up |
| Ireland | 63670 | Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds | ⤷ Sign Up |
| Hungary | 197008 | PROCESS FOR PRODUCING HEXAHYDRO-8-HYDROXY-2,6-METHANO-2H-QUINOLIZIN-3(4H)-ONE ESTERS AND DERIVATIVES | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ANZEMET
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0266730 | 98C0014 | Belgium | ⤷ Sign Up | PRODUCT NAME: MIGLITOL; NAT. REGISTRATION NO/DATE: NL 22 138 19970204; FIRST REGISTRATION: NL - 19 343 UR 19960723 |
| 0266730 | C970043 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DOLASETRON, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; NAT REGISTRATION NO/DATE: RVG 21707 - RVG 21709 19970623; FIRST REGISTRATION: GB PL 04425/0150, PL 04425/0152, PL 04425/0154 19960926 |
| 0266730 | 73/1997 | Austria | ⤷ Sign Up | PRODUCT NAME: ANZEMET; NAT. REGISTRATION NO/DATE: 1-22014, 1-22015, 1-22016 19970624; FIRST REGISTRATION: GB PL 04425/0150 19960926 |
| 0266730 | SPC/GB97/005 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
